Deutsche Bank turns bearish on Novartis as shares recover failed trial losses
Deutsche Bank downgraded Novartis (NOVN) to 'sell' from 'hold', cutting its price target to CHF115 from CHF120. The bank cited the stock's recovery from failed drug trials and a 'somewhat mixed' third quarter. Novartis reported Q3 core EPS of $2.46, beating estimates, but revenue missed. The stock trades at a P/E of 31.11, 6% below its 52-week high.
How this was made
The 30-second read
Why it matters
Analyst downgrade likely triggers short‑term sell pressure, though longer‑term fundamentals remain mixed.
Market read
The downgrade provides a fresh catalyst for traders to consider short positions in Novartis.
What to watch
Novartis' recent profit outlook raise and cost controls could offset short‑term concerns.
Background
Novartis recently reported Q3 earnings with mixed results and a profit outlook raise, but two drug trial failures prompted a downgrade.
Ticker impact
Deutsche Bank downgraded Novartis to sell and cut its price target to CHF115 from CHF120.
downward pressure as the market prices in the lower target and sell rating.
Analyst downgrade with a reduced target typically leads to short-term sell-offs.
Market effects
Potential drag on the broader pharmaceutical sector as peers may face similar scrutiny.
European markets may see modest weakness in healthcare stocks.
Limited to pharma and biotech investors; no broad market effect.
Counterpoint
The downgrade may be premature if upcoming trial data exceeds expectations.
Key entities
- companyNovartis
Swiss pharmaceutical giant, ticker NVS.
- financial_institutionDeutsche Bank
Issued the downgrade and new price target.
